慢性移植物抗宿主病的治疗进展

邓陶然; 肖毅

doi:10.3969/j.issn.1674-7445.2016.01.014

慢性移植物抗宿主病的治疗进展

doi: 10.3969/j.issn.1674-7445.2016.01.014

邓陶然,
肖毅^,

430030 武汉, 华中科技大学同济医学院附属同济医院血液内科

基金项目:

湖北省科技计划项目 2012FFB02435

详细信息

通讯作者:
肖毅, Email:yixiao@tjh.tjmu.edu.cn

中图分类号: R617;R392.4
计量
- 文章访问数: 136
- HTML全文浏览量: 64
- PDF下载量: 10
- 被引次数: 0
出版历程
- 收稿日期: 2015-09-20
- 网络出版日期: 2021-01-19
- 刊出日期: 2016-01-15

摘要

摘要: 慢性移植物抗宿主病(cGVHD)是异基因造血干细胞移植(allo-HSCT)的主要后期并发症, 严重影响患者的生存质量, 是导致非复发性死亡的重要原因。cGVHD的治疗一直是移植领域研究的重要内容之一。目前肾上腺皮质激素(激素)是cGVHD的核心治疗药物, 常联用钙神经蛋白抑制剂(CNI)作为一线治疗方案。长期激素治疗往往带来严重不良反应, 而新的治疗方法, 如哺乳动物雷帕霉素靶蛋白抑制剂、利妥昔单抗、间充质干细胞等可避免广泛的免疫毒性, 有治疗cGVHD的巨大潜力。
- 慢性移植物抗宿主病 /
- 肾上腺皮质激素 /
- 光化学疗法 /
- 间充质干细胞

HTML全文

参考文献(37)

[1]	Socié G, Ritz J. Current issues in chronic graft-versus-host disease[J]. Blood, 2014, 124(3):374-384. doi: 10.1182/blood-2014-01-514752
[2]	Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:I. diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005, 11(12):945-956. doi: 10.1016/j.bbmt.2005.09.004
[3]	Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD):first-line and topical treatment of chronic GVHD[J]. Biol Blood Marrow Transplant, 2010, 16(12):1611-1628. doi: 10.1016/j.bbmt.2010.06.015
[4]	Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease:a randomized trial comparing cyclosporine plus prednisone versus prednisone alone[J]. Blood, 2002, 100(1):48-51. doi: 10.1182/blood.V100.1.48
[5]	Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease[J]. Hematology Am Soc Hematol Educ Program, 2008:134-141. https://www.ncbi.nlm.nih.gov/pubmed/19074071
[6]	Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.[J]. Blood, 1988, 72(2):555-561. https://www.ncbi.nlm.nih.gov/pubmed/3042042
[7]	Sullivan KM, Siadak MF, Witherspoon RP. Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation[J]. Transplant Proc, 1990, 22(3):1336-1338. https://www.ncbi.nlm.nih.gov/pubmed/2190396
[8]	Jung JW, Lee YJ, Yoon SC, et al. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease[J]. Am J Ophthalmol, 2015, 159(3):519-527. doi: 10.1016/j.ajo.2014.11.035
[9]	Sullivan KM, Witherspoon RP, Storb R, et al.Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease:prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation[J]. Blood, 1988, 72(2):546-554. https://www.ncbi.nlm.nih.gov/pubmed/3042041
[10]	Linhares YP, Pavletic S, Gale RP. Chronic GVHD:where are we? where do we want to be? will immunomodulatory drugs help?[J]. Bone Marrow Transplant, 2013, 48(2):203-209. doi: 10.1038/bmt.2012.76
[11]	Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2001, 7(5):265-273. doi: 10.1053/bbmt.2001.v7.pm11400948
[12]	Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease[J]. Blood, 2000, 96(12):3995-3996. https://www.ncbi.nlm.nih.gov/pubmed/11090092
[13]	Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease[J]. Blood, 1995, 86(9):3604-3609. https://www.ncbi.nlm.nih.gov/pubmed/7579470
[14]	Nassar A, Elgohary G, Elhassan T, et al. Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. J Transplant, 2014:980301. https://www.ncbi.nlm.nih.gov/pubmed/25405023
[15]	Busca A, Locatelli F, Marmont F, et al. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease[J]. Haematologica, 2003, 88(7):837-839.
[16]	Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease[J]. Blood, 2009, 113(21):5074-5082. https://www.ncbi.nlm.nih.gov/pubmed/19270260
[17]	Iida M, Fukuda T, Uchida N, et al. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan[J]. Clin Transplant, 201428(9):980-989. doi: 10.1111/ctr.2014.28.issue-9
[18]	Olivieri J, Coluzzi S, Attolico I, et al. Tirosin kinase inhibitors in chronic graft versus host disease:from bench to bedside[J]. ScientificWorldJournal, 2011, 11:1908-1931. doi: 10.1100/2011/924954
[19]	Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features[J]. Blood, 2009, 114(3):709-718. doi: 10.1182/blood-2009-02-204156
[20]	Olivieri A, Cimminiello M, Corradini P, et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD[J]. Blood, 2013, 122(25):4111-4118. doi: 10.1182/blood-2013-05-494278
[21]	Baird K, Comis LE, Joe GO, et al. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2015, 21(6):1083-1090. doi: 10.1016/j.bbmt.2015.03.006
[22]	Yu K, Toral-Barza L. Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor[J]. Methods Mol Biol, 2012, 821:15-28. doi: 10.1007/978-1-61779-430-8
[23]	Lutz M, Kapp M, Einsele H, et al. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus[J]. Clin Transplant, 2014, 28(12):1410-1415. doi: 10.1111/ctr.2014.28.issue-12
[24]	Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab:a GITMO study[J]. Bone Marrow Transplant, 2007, 40(3):273-277. doi: 10.1038/sj.bmt.1705725
[25]	Bates JS, Engemann AM, Hammond JM. Clinical utility of rituximab in chronic graft-versus-host disease[J]. Ann Pharmacother, 2009, 43(2):316-321. https://www.ncbi.nlm.nih.gov/pubmed/19193571
[26]	Arai S, Pidala J, Pusic I, et al. A randomized phase Ⅱ crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation[J]. Clin Cancer Res, 2015, DOI: 10.1158/1078-0432.CCR-15-1443.
[27]	Solomon SR, Sizemore CA, Ridgeway M, et al. Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab[J]. Biol Blood Marrow Transplant, 2015, 21(9):1576-1582. doi: 10.1016/j.bbmt.2015.04.023
[28]	Lawitschka A, Ball L, Peters C. Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents[J]. Biol Blood Marrow Transplant, 2012, 18(1 Suppl):S74-S81. https://www.ncbi.nlm.nih.gov/pubmed/22226116
[29]	Malik MI, Litzow M, Hogan W, et al. Extracorporeal photopheresis for chronic graft-versus-host disease:a systematic review and meta-analysis[J]. Blood Research, 2014, 49(2):100-106. doi: 10.5045/br.2014.49.2.100
[30]	周林, 杜国盛.体外光分离置换疗法与器官移植[J].器官移植, 2014, 5(2):119-122. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201402017.htm Zhou L, Du GS. Extracorporeal photopheresis in organ transplantation[J]. Organ Transplant, 2014, 5(2):119-122. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201402017.htm
[31]	Ballester-Sánchez R, Navarro-Mira MÁ, de Unamuno-Bustos B, et al. The role of phototherapy in cutaneous chronic graft-vs-host disease:a retrospective study and review of the literature[J]. Actas Dermosifiliogr, 2015, 106(8):651-657. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_gwyx-sxjxyxfc201304008
[32]	翁建宇.间充质干细胞治疗慢性移植物抗宿主病研究进展[J].国际输血及血液学杂志, 2013, 36(4):406-409. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_gwyx-sxjxyxfc201304008 Weng JY. Research progress on mesenchymal stem cells for the treatment of chronic graft versus host disease[J]. Int J Blood Transfus Hematol, 2013, 36(4):406-409. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_gwyx-sxjxyxfc201304008
[33]	Peng Y, Chen X, Liu Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5⁺ regulatory B cells producing interleukin 10[J]. Leukemia, 2015, 29(3):636-646. doi: 10.1038/leu.2014.225
[34]	Peng Y, Chen X, Liu Q, et al. Alteration of na?ve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells[J]. Cells Transl Med, 2014, 3(9):1023-1031. doi: 10.5966/sctm.2014-0001
[35]	Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease:clinical report[J]. Biol Blood Marrow Transplant, 2010, 16(3):403-412. doi: 10.1016/j.bbmt.2009.11.006
[36]	Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease:a phase 1 study[J]. Int J Hematol, 2012, 95(2):182-188. doi: 10.1007/s12185-011-0989-2
[37]	Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD[J]. Bone Marrow Transplant, 2010, 45(12):1732-1740. doi: 10.1038/bmt.2010.195